Stewart Grote
Internal Medicine · Lansing, KSNPI 1902898968
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 273 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,288 and has fallen 61.9% since, to $490 in 2025. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AstraZeneca$565
- Mannkind Corporation$490
- Lilly USA, LLC$440
- GSK$363
- Amgen$219
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,93499%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 63 | $1,006 |
| AstraZeneca | 25 | $565 |
| Mannkind Corporation | 36 | $490 |
| Lilly USA, LLC | 27 | $440 |
| GSK | 9 | $363 |
| Amgen | 14 | $219 |
| Amarin Pharma, Inc. | 6 | $179 |
| Sunovion Pharmaceuticals Inc. | 18 | $178 |
| Bayer | 10 | $165 |
| AbbVie(2 entities) | 7 | $155 |
| Astellas Pharma US Inc | 4 | $142 |
| Organogenesis Inc. | 8 | $138 |
| Aspira Women's Health Inc | 5 | $121 |
| E.r. Squibb & Sons, L.L.C. | 1 | $106 |
| Merck | 6 | $98 |
| Mylan Specialty L.p. | 5 | $90 |
| Johnson & Johnson | 5 | $77 |
| Alkermes, Inc. | 2 | $54 |
| Viatris Specialty LLC | 2 | $46 |
| Electromed, Inc. | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Pfizer | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Philips North America LLC | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Indivior Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,968 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 20 | $21,854 |
| OzempicSemaglutide | 12 | $11,220 |
| KerendiaFinerenone | 14 | $8,954 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,212 |
| Gabapentin | 43 | $1,601 |
| Triamcinolone Acetonide | 15 | $831 |
| Celecoxib | 18 | $826 |
| Bupropion XlBupropion Hcl | 11 | $487 |
| Tizanidine Hcl | 31 | $466 |
| Tamsulosin Hcl | 32 | $342 |
| Hydroxychloroquine Sulfate | 22 | $311 |
| Olanzapine | 11 | $292 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $208 |
| Carvedilol | 36 | $206 |
| Prednisone | 28 | $196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Olanzapine | $440 | $22,14731 claims |
| Novo NordiskOzempic | $20 | $11,22012 claims |
| BayerKerendia | $165 | $8,95414 claims |
| GSKAnoro Ellipta | $363 | $5,21211 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $8733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Lansing
- Shadi HamdehKansas City$959K
- Donna GriebelLawrence$781K
- Lucas PittsKansas City$235K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Mark HamblinKansas City$147K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
- Aaron RohrKansas City$54K
- Raed Al RajabiWestwood$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.